113 related articles for article (PubMed ID: 28905237)
1.
Wang Y; Pinet L; Assrir N; Elantak L; Guerlesquin F; Badache A; Lescop E; van Heijenoort C
Biomol NMR Assign; 2018 Apr; 12(1):23-26. PubMed ID: 28905237
[TBL] [Abstract][Full Text] [Related]
2. Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random.
Pinet L; Wang YH; Deville C; Lescop E; Guerlesquin F; Badache A; Bontems F; Morellet N; Durand D; Assrir N; van Heijenoort C
Biophys J; 2021 May; 120(10):1869-1882. PubMed ID: 33741354
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
4. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers.
Sharpe S; Barber KR; Grant CW
Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Src kinase SH3 binding site in the C-terminal domain of the human ErbB2 receptor tyrosine kinase.
Bornet O; Nouailler M; Feracci M; Sebban-Kreuzer C; Byrne D; Halimi H; Morelli X; Badache A; Guerlesquin F
FEBS Lett; 2014 Jun; 588(12):2031-6. PubMed ID: 24815698
[TBL] [Abstract][Full Text] [Related]
6. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases.
Mineev KS; Bocharov EV; Pustovalova YE; Bocharova OV; Chupin VV; Arseniev AS
J Mol Biol; 2010 Jul; 400(2):231-43. PubMed ID: 20471394
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Transmembrane Domain Interactions in Neu Receptor Tyrosine Kinase by Membrane Fluidity and Cholesterol.
Hasan M; Patel D; Ellis N; Brown SP; Lewandowski JR; Dixon AM
J Membr Biol; 2019 Oct; 252(4-5):357-369. PubMed ID: 31222471
[TBL] [Abstract][Full Text] [Related]
8. A putative molecular-activation switch in the transmembrane domain of erbB2.
Fleishman SJ; Schlessinger J; Ben-Tal N
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15937-40. PubMed ID: 12461170
[TBL] [Abstract][Full Text] [Related]
9. Backbone and side chain resonance assignments of the C-terminal domain of human TGIF1.
Cai C; Nie Y; Yue X; Zhu J; Hu R; Liu M; Yang Y
Biomol NMR Assign; 2019 Oct; 13(2):357-360. PubMed ID: 31388821
[TBL] [Abstract][Full Text] [Related]
10. A CON-based NMR assignment strategy for pro-rich intrinsically disordered proteins with low signal dispersion: the C-terminal domain of histone H1.0 as a case study.
Chaves-Arquero B; Pantoja-Uceda D; Roque A; Ponte I; Suau P; Jiménez MA
J Biomol NMR; 2018 Dec; 72(3-4):139-148. PubMed ID: 30414042
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
12. Backbone
Conroy BS; Weiss ER; Smith SP; Langelaan DN
Biomol NMR Assign; 2017 Apr; 11(1):95-98. PubMed ID: 28247282
[TBL] [Abstract][Full Text] [Related]
13. Backbone and side-chain assignments of a tethered complex between LMO4 and DEAF-1.
Joseph S; Kwan AH; Mackay JP; Cubeddu L; Matthews JM
Biomol NMR Assign; 2014 Apr; 8(1):141-4. PubMed ID: 23417771
[TBL] [Abstract][Full Text] [Related]
14. H(N), N, C(α), C(β) and C' assignments of the intrinsically disordered C-terminus of human adenosine A2A receptor.
Tossavainen H; Hellman M; Piirainen H; Jaakola VP; Permi P
Biomol NMR Assign; 2015 Oct; 9(2):403-6. PubMed ID: 25952762
[TBL] [Abstract][Full Text] [Related]
15. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
16. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7.
Janes PW; Lackmann M; Church WB; Sanderson GM; Sutherland RL; Daly RJ
J Biol Chem; 1997 Mar; 272(13):8490-7. PubMed ID: 9079677
[TBL] [Abstract][Full Text] [Related]
18. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.
Mukherji M; Brill LM; Ficarro SB; Hampton GM; Schultz PG
Biochemistry; 2006 Dec; 45(51):15529-40. PubMed ID: 17176074
[TBL] [Abstract][Full Text] [Related]
19. Backbone nuclear relaxation characteristics and calorimetric investigation of the human Grb7-SH2/erbB2 peptide complex.
Ivancic M; Spuches AM; Guth EC; Daugherty MA; Wilcox DE; Lyons BA
Protein Sci; 2005 Jun; 14(6):1556-69. PubMed ID: 15930003
[TBL] [Abstract][Full Text] [Related]
20. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
